Hyloris Developmentsen Sa
HYL.BR
| Exchange: | BR |
| Currency | Euro |
| ISIN: | BE0974363955 |
| LEI: | 875500LZIWS7QEQE0I73 |
| Primary Ticker: | HYL.BR |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Biotechnology |
| Gic Sub Industry: | Biotechnology |
| Description: | Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium. |
| Address: | Boulevard Patience et Beaujonc N°3/1, Liège, Belgium, 4000 |
| Website: | https://hyloris.com |
| Full Time Employees: | 41 |
| Updated On: | 2024-11-05 |
Highlights
| Market Capitalization: | 159502208 |
| Market Capitalization Mln: | 159.50 |
| EBITDA: | -13525000 |
| Wall Street Target Price: | 19.1 |
| Book Value: | 1.19 |
| Earnings Share: | -0.55 |
| Most Recent Quarter: | 2023-12-31 |
| Profit Margin: | -1.90 |
| Operating Margin TTM: | -0.84 |
| Return On Assets TTM: | -0.16 |
| Return On Equity TTM: | -0.31 |
| Revenue TTM: | 6941000 |
| Revenue Per Share TTM: | 0.24 |
| Quarterly Revenue Growth YOY: | 1.42 |
| Gross Profit TTM: | 2857000 |
| Diluted Eps TTM: | -0.55 |
Valuation
| Price Sales TTM: | 22.97 |
| Price Book MRQ: | 4.01 |
| Enterprise Value: | 128147094 |
| Enterprise Value Revenue: | 61.40 |
| Enterprise Value Ebitda: | -39.56 |
Shares
| Shares Outstanding: | 28000400 |
| Shares Float: | 12536706 |
| Percent Insiders: | 56.62 |
| Percent Institutions: | 0.11 |
Technicals
| Beta: | 0.45 |
| 52 Week High: | 13.3 |
| 52 Week Low: | 2.89 |
| 50 Day MA: | 5.88 |
| 200 Day MA: | 9.94 |
Earnings
| Report Date: | 2023-03-15 |
| Date: | 2022-12-31 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | -0.38 |
| Eps Difference: | -0.38 |
| Report Date: | 2022-09-01 |
| Date: | 2022-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.19 |
| Eps Difference: | -0.19 |
| Report Date: | 2022-04-29 |
| Date: | 2022-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.13 |
| Eps Difference: | -0.13 |
| Report Date: | 2021-08-04 |
| Date: | 2021-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.32 |
| Eps Difference: | -0.32 |
| Report Date: | 2021-04-30 |
| Date: | 2021-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.33 |
| Eps Difference: | -0.33 |
| Report Date: | 2020-08-06 |
| Date: | 2020-06-30 |
| Before After Market: | After Market |
| Currency: | EUR |
| Eps Actual: | -0.12 |
| Report Date: | 2020-06-17 |
| Date: | 2020-03-31 |
| Currency: | EUR |
| Eps Actual: | -0.36 |
| Eps Difference: | -0.36 |
| Date: | 2022-12-31 |
| Eps Actual: | -1.8 |